This week (April 25-29), a total of 8 new shares were listed, of which 4 broke on the first day, all of which were new shares on the science and innovation board.
It is worth noting that among the 43 new shares listed on the science and innovation board this year, 25 broke on the first day, accounting for 58%. Nevertheless, the overall performance of Kechuang board company is obviously improving. The data show that in 2021, the operating revenue and net profit of Kechuang board company increased significantly year-on-year, and the growth is higher than that of other sectors; In the first quarterly report, the net profit of 101 Sci-tech Innovation Board companies increased by more than 50%.
four new shares broke on the first day of this week
A total of 8 new shares were listed this week, of which 4 were broken on the first day, all of which were new shares on the science and innovation board.
Among them, the largest drop in the first day was Yaokang biology. On April 25, the initial price of Yaokang biology, which landed on the science and innovation board, was 22.53 yuan. It broke off on the first day of listing and fell to 17.04 yuan as low as before. If the winning shareholders sell at this price, the maximum loss of 500 shares in the first lot is 2745 yuan. As of the close, the share price fell 17.89% to 18.50 yuan.
Trend of Yaokang biology on the first day of listing
Yaokang biology, founded in 2017, is a high-tech enterprise specializing in the R & D, production, sales and related technical services of experimental animal mouse models. It is a member of the Asian mouse mutation and resource alliance and a co construction unit of the national genetic engineering mouse resource bank recognized by the Ministry of science and technology. Among them, the sales types of Yaokang biological commercialized mouse models include spotted mice, immune deficiency mouse models, humanized mouse models, disease mouse models and basic strain mice.
Yaokang biology originally planned to raise 820 million yuan, but the net amount of funds actually raised was 1.026 billion yuan, exceeding 200 million yuan. It is worth noting that the shareholder lineup of Yaokang biology is also relatively luxurious, attracting international well-known investment institutions such as Hillhouse and Sequoia.
On April 28, the issuance price of Hechuan technology, which landed on the science and innovation board, was 23.66 yuan. It also broke at the opening and fell 16.74% to 19.70 yuan as of the closing.
Trend of Hechuan technology on the first day of listing
Founded in 2011, Hechuan technology is a technology driven provider of core components and overall solutions for industrial automation control. It is mainly engaged in the R & D, production, sales and application integration of industrial automation products. Its products include servo system, PLC, etc., covering the control layer, driving layer and executive sensing layer in the field of industrial automation. In recent years, Hechuan technology has continuously extended along the upstream and downstream of the industrial chain and set foot in the upstream industrial control chips Sensors and downstream high-end precision CNC machine tools.
The latest disclosed quarterly report shows that in the first quarter of this year, Hechuan technology achieved an operating revenue of 191 million yuan, a year-on-year increase of 14.86%, and a net profit of 19.871 million yuan, a year-on-year decrease of 17.37%.
the issuance of new shares on the science and Innovation Board increased
At present, the sentiment in the new market is poor. Of the 122 new shares listed on the A-share market this year, 36 shares have broken on the first day, accounting for 30%.
It is worth noting that among the 43 new shares listed on the science and innovation board this year, 25 broke on the first day, accounting for 58%. The biggest decline on the first day was Weijie chuangxin-u, which fell 36.04% on the first day.
Market institutions generally believe that the recent issuance of new shares is affected by the overall downturn of the secondary market, and some quotation institutions lack expectation and adjustment for the changes of the secondary market and fail to adjust the quotation strategy in time. Taking the new shares of the science and innovation board as an example, there are 5 new shares with an issue price of more than 100 yuan this year, and 12 new shares with a P / E ratio of more than 100 times.
Despite the increase in breaking points, the overall performance of Kechuang board company is obviously improving. The data show that in 2021, the operating revenue and net profit of Kechuang board company increased significantly year-on-year, and the growth is higher than that of other sectors; In the first quarterly report, the net profit of 101 Sci-tech Innovation Board companies increased by more than 50%.
In addition, the data show that since this year, the median rise and fall of new shares on the science and Innovation Board on the first day has been – 6.37%, and the average rise and fall on the first day has been 3.79%. The overall income is still positive.
In 2022, the trend of Shanghai and Shenzhen fluctuated more. As of the closing on April 29, 75 of the 122 new shares listed this year have broken the latest share price, accounting for 61%. In terms of the increase list, among the new shares listed this year, Hefu China still has the highest cumulative increase. After listing, Hefu China once had 12 boards, with a cumulative increase of more than 189%, and Hefu China is also the new share with the largest number of boards this year.
It is worth noting that the breaking of new shares has attracted the attention of regulators. Recently, the Shanghai Stock Exchange organized a number of securities companies to hold a symposium to discuss the current market breaking phenomenon. The main underwriters attending the meeting believed that after the adjustment of the new inquiry regulations of the science and innovation board, the mechanism was fully and effectively operated and the trading game was deepened. The recent breaking rate is high, which belongs to a phased phenomenon in the process of market-oriented reform.
At the symposium, the Shanghai Stock Exchange stressed that each lead underwriter should carefully write the investment value report in accordance with the norms and requirements of the association, fully carry out investor roadshow communication, manage the issuer’s valuation and pricing expectations, reasonably plan the raised investment projects, and carefully determine the issuance price after fully considering the market, industry and underwriting risks. Next, consider including the indicators such as “large proportion breaking” into the practice quality evaluation of the lead underwriter.
